Biohaven’s Taldefgrobep Alfa Fails to Achieve Statistical Significance in Treating Spinal Muscular Atrophy

Results of the RESILIENT SMA study found that while taldefgrobep demonstrated clinically meaningful motor function improvements in patients with spinal muscular atrophy, the treatment arm did not achieve statistical significance at 48 weeks.